OLEMA ONCOLOGY
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. The company focuses on the discovery, development, and commercialization of targeted therapies for women's cancers. It leverages the knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development. Olema leverages their deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies.
OLEMA ONCOLOGY
Industry:
Biopharma Biotechnology Health Care Medical Pharmaceutical
Founded:
2007-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.olema.com
Total Employee:
11+
Status:
Active
Contact:
4157428265
Email Addresses:
[email protected]
Total Funding:
145.05 M USD
Technology used in webpage:
Google Font API Font Awesome Mobile Non Scaleable Content Nginx DigiCert SSL Digital Ocean RapidSSL Nginx 1.17
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
PanTheryx
PanTheryx is a nutrition and biotechnology company that utilizes the cellular and biomolecular processes of bovine colostrum.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
OrbiMed
OrbiMed investment in Series C - Olema Oncology
Cormorant Asset Management
Cormorant Asset Management investment in Series C - Olema Oncology
Deerfield
Deerfield investment in Series C - Olema Oncology
Avoro Capital Advisors
Avoro Capital Advisors investment in Series C - Olema Oncology
Wellington Management
Wellington Management investment in Series C - Olema Oncology
RA Capital Management
RA Capital Management investment in Series C - Olema Oncology
Venrock
Venrock investment in Series C - Olema Oncology
BVF Partners
BVF Partners investment in Series C - Olema Oncology
Logos Capital
Logos Capital investment in Series C - Olema Oncology
Vivo Capital
Vivo Capital investment in Series C - Olema Oncology
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-31 | Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.olema.com Semrush global rank: 2.41 M Semrush visits lastest month: 7.51 K
- Host name: 107.55.224.35.bc.googleusercontent.com
- IP address: 35.224.55.107
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Olema Oncology"
Olema Oncology - Innovating medicines for breast cancer and …
November 12th, 2024 Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update. Presented compelling new preclinical data demonstrating anti …See details»
Olema Oncology - Crunchbase Company Profile
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. The company focuses on the discovery, development, and commercialization of …See details»
Olema Oncology – Join our team and make your mark
Olema is committed to cultivating an open, flexible, and supportive work environment with competitive compensation and benefits. We empower our …See details»
Olema Oncology - LinkedIn
Olema Oncology is a cancer medicines company dedicated to impacting breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a differentiated oral medicine known as a complete ...See details»
Olema Oncology - Contacts, Employees, Board Members
Organization. Olema Oncology . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 8. Number of …See details»
Olema Oncology – Better medicines for breast cancer and beyond …
Dec 31, 2022 SAN FRANCISCO, March 09, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage …See details»
Olema Oncology Company Profile - Office Locations, Competitors …
Oct 29, 2024 Olema Oncology (also known as Olema Pharmaceuticals) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies …See details»
Olema Oncology - Funding, Financials, Valuation & Investors
Olema Oncology is registered under the ticker NASDAQ:OLMA . Their stock opened with $19.00 in its Nov 19, 2020 IPO. Stock Symbol NASDAQ:OLMA ; Valuation at IPO $731.9M; Money …See details»
Olema Oncology Announces New Clinical Trial Collaboration and …
7 hours ago Olema well capitalized to fund operations beyond key milestones including OPERA-01 Phase 3 top-line data in 2026, initial OP-3136 KAT6 Phase 1/2 monotherapy and …See details»
Olema Oncology Reports First Quarter 2021 Financial Results and ...
“The first quarter of 2021 was very productive for Olema as we continued to advance our wholly-owned lead candidate, OP-1250, a complete estrogen receptor (ER) antagonist (CERAN), …See details»
Supporting patients and their families. - Olema
At Olema, we are inspired by people and their stories and are determined to develop safer, more effective and convenient medicines to signal in a new day for those impacted by metastatic …See details»
Olema Oncology – Better medicines for breast cancer and beyond …
19 hours ago Olema well capitalized to fund operations beyond key milestones including OPERA-01 Phase 3 top-line data in 2026, initial OP-3136 KAT6 Phase 1/2 monotherapy and …See details»
Olema Oncology Partners With Novartis For Phase 3 Trial In Breast ...
6 hours ago Olema Oncology (), a clinical-stage biopharmaceutical company, on Monday announced a new clinical trial collaboration and supply agreement with Novartis (NVS) to …See details»
Olema Pharmaceuticals (OLMA) Announces New Clinical Trial …
6 hours ago Olema intends to use the net proceeds from the Private Placement, together with its current cash, cash equivalents and marketable securities, to fund the OPERA-02 trial, the …See details»
Olema Oncology – Recent publications
Apr 4, 2012 A phase 1b/2 dose escalation and dose expansion study of OP-1250, an oral complete estrogen receptor antagonist (CERAN)/selective estrogen receptor degrader …See details»
Olema Oncology – Better medicines for breast cancer and beyond …
Jun 9, 2022 Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. About Aurigene Aurigene Discovery Technologies Limited is a clinical stage …See details»
Olema Oncology Announces New Clinical Trial Collaboration and …
7 hours ago New Clinical Trial Collaboration and Supply Agreement Enables Phase 3 OPERA-02 Trial Under the terms of the agreement, Novartis will provide Olema with ribociclib drug …See details»
Olema Oncology Announces New Clinical Trial ... - Markets Insider
7 hours ago Olema well capitalized to fund operations beyond key milestones including OPERA-01 Phase 3 top-line data in 2026, initial OP-3136 KAT6 Phase 1/2 monotherapy and …See details»
Olema Pharmaceuticals (OLMA) Earnings Date and Reports 2025
Nov 25, 2024 Olema Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 10th, 2025 based off last year's …See details»
Iterating with the insight of expertise. - Olema
At Olema, we are committed to improving outcomes for people with metastatic breast cancer. Palazestrant (OP-1250) is a novel investigational agent with combined activity as both a next …See details»